Skip to main content

Site notifications

We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.

Sub menu

News and events
Contact us
About us

Search

Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

You are here

Home
Resources and guidance
Sponsors

Juno Pharmaceuticals Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (261)
Cancellation by sponsor (83)
Prescription medicine registration (28)
Section 14, TGO91 consent (6)
Australian public assessment report (AusPar) (1)
Prescription medicine decision summary (1)

Date

2026 (3)
2025 (23)
2024 (13)
2023 (18)
2022 (35)
2021 (68)
2020 (45)
2019 (51)
2018 (18)
2017 (14)
2016 (17)
2015 (14)
2014 (7)
2013 (8)
2012 (12)
2011 (5)
2010 (1)
2009 (2)
2007 (1)
2006 (4)
2003 (7)
2000 (1)
1999 (2)
1998 (1)
1996 (3)
1994 (2)
1991 (5)

Search

Sponsor content

380 result(s) found, displaying 191 to 200

HYDROMORPHONE JUNO-XHP hydromorphone hydrochloride 50 mg/1 mL concentrated injection ampoules (303505)

6 May 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for HYDROMORPHONE JUNO-XHP hydromorphone hydrochloride 50 mg/1 mL concentrated injection ampoules.
HYDROMORPHONE JUNO-HP hydromorphone hydrochloride 50 mg/5 mL injection solution ampoules (303504)

6 May 2019

ARTG

Australian Register of Therapeutic Goods (ARTG) information for HYDROMORPHONE JUNO-HP hydromorphone hydrochloride 50 mg/5 mL injection solution ampoules.
TRANEXAMIC ACID JN tranexamic acid 1000 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

8 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TRANEXID tranexamic acid 500mg/5mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

8 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TRANEXID tranexamic acid 1000 mg/10 mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

8 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
TRANEXAMIC ACID JN tranexamic acid 500mg/5mL solution for injection ampoule Cancelled under Section 30(1)(c) of the Act

8 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
CISATRACURIUM HHH cisatracurium (as besilate) 150mg/30mL Solution for Injection vial Cancelled under Section 30(1)(c) of the Act

5 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
CISATRACURIUM HHH cisatracurium (as besilate) 20mg/10mL Solution for Injection ampoule Cancelled under Section 30(1)(c) of the Act

5 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
CISATRACURIUM HHH cisatracurium (as besilate) 5mg/2.5mL Solution for Injection ampoule Cancelled under Section 30(1)(c) of the Act

5 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd
CISATRACURIUM HHH cisatracurium (as besilate) 10mg/5mL Solution for Injection ampoule Cancelled under Section 30(1)(c) of the Act

5 July 2021

Cancellation by sponsor

Requested by Juno Pharmaceuticals Pty Ltd

Pages

First page
Previous page
…
Page 16
Page 17
Page 18
Page 19
Current page 20
Page 21
Page 22
Page 23
Page 24
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

© Commonwealth of Australia